Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis.
Giovanna
G
Riolo
Tanveer E
TE
Towheed
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology; D003882:Dermatomyositis / Q000139:chemically induced* / Q000473:pathology; D004487:Edema / Q000139:chemically induced; D005208:Fasciitis / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab